Navigation Links
Sangamo BioSciences Provides Update on Diabetic Neuropathy Clinical Programs
Date:6/6/2008

f stages of the SB-509 clinical trials, whether the SB-509 clinical trials will validate and support tolerability and efficacy of SB-509, technological challenges, Sangamo's ability to develop commercially viable products and technological developments by our competitors. See Sangamo's SEC filings, and in particular, the risk factors described in its Annual Report on Form 10-K and its most recent Quarterly Report on Form 10-Q. Sangamo BioSciences, Inc. assumes no obligation to update the forward-looking information contained in this press release.


'/>"/>
SOURCE Sangamo BioSciences, Inc.
Copyright©2008 PR Newswire.
All rights reserved

1

GOOD

Page: 1 2 3 4 5

Related medicine technology :

1. Sangamo BioSciences Announces Presentation of Data on ZFP Therapeutic for Glioblastoma at American Association for Cancer Research (AACR) Meeting
2. Sangamo BioSciences and Sigma-Aldrich Announce Publication of Study Demonstrating Zinc Finger Technology for Rapid Generation of Knock-Out Cell Lines
3. Sangamo BioSciences Reports 2007 Fourth Quarter and Year-End Financial Results
4. Sangamo BioSciences Announces Completion of Enrollment of Phase 2 Clinical Trial of ZFP Therapeutic for Diabetic Neuropathy
5. Sangamo BioSciences and Sigma-Aldrich Announce Nature Biotechnology Study Demonstrating Zinc Finger Technology for Modification of Human Stem Cells
6. Regado Biosciences Announces Publication in Circulation of Clinical Trial Results of REG1 Anticoagulation System
7. Magellan Biosciences Companies to Feature Automated Products and New Tests for MRSA at the American Society for Microbiology Meeting, Booth 743
8. Ardea Biosciences Presents Preclinical Data on RDEA119 Demonstrating Favorable Anti-Inflammatory Profile for Potential Use in Ulcerative Colitis
9. Ardea Biosciences Identifies Lead Development Candidate for Gout, RDEA594
10. Ardea Biosciences Appoints John W. Beck Chief Financial Officer, Announces Clinical Development Progress and Reports First Quarter 2008 Financial Results
11. Catalyst Biosciences Selects Drug Development Candidate in Factor VIIa Program for Hemophilia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/18/2008)...der with Strong Clinical Research Relationships an...ations to Lead Commercialization, SANTA CLARA, Ca... Inc.,(OTC Bulletin Board: NWCI) a cardiac diagno...ncent W. Renz has joined NewCardio as its presiden...zation effort, to include,business development, cl...
(Date:8/17/2008)...tralia, Aug. 17 /Xinhua-- P...that the first pivotal Phase 3,clinical trial of B...,completed enrolment., The first efficacy data fr...e first half of 2009. The trial commenced its dosi...tment target of 250 subjects in June,2008 and clos...
(Date:8/14/2008)...A Complimentary Continuing Education Activity, VO...rus (CMV) is a,significant cause of morbidity and ... transplantation. The clinical manifestations of C...inal disease to life-threatening,pneumonia, myelos...r to prevent CMV infection and reduce CMV drug res...
(Date:8/14/2008)...EACH, Fla., Aug. 14 /- The Clinical T...ed at educating physicians,clinical coordinators,...,clinical trial. It will be held in Boca Raton at ...investigators, clinical coordinators, monitors and... about how to incorporate,clinical trials into a p...
Breaking Medicine Technology:Vincent W. Renz Joins NewCardio as President 2Vincent W. Renz Joins NewCardio as President 3Vincent W. Renz Joins NewCardio as President 4Bronchitol Phase 3 Cystic Fibrosis Trial Completes Recruitment 2CMV Disease in Stem Cell Transplantation: Prevention and Drug Resistance 2Previously Disclosed Changes in Board Composition of NightHawk Radiology Holdings Inc Prompt Notice of Noncompliance from the Nasdaq Global Market 14205 1Previously Disclosed Changes in Board Composition of NightHawk Radiology Holdings Inc Prompt Notice of Noncompliance from the Nasdaq Global Market 14205 2WuXi PharmaTech Announces Fourth Quarter and Full Year 2007 Results 3916 1WuXi PharmaTech Announces Fourth Quarter and Full Year 2007 Results 3916 2WuXi PharmaTech Announces Fourth Quarter and Full Year 2007 Results 3916 3WuXi PharmaTech Announces Fourth Quarter and Full Year 2007 Results 3916 4WuXi PharmaTech Announces Fourth Quarter and Full Year 2007 Results 3916 5WuXi PharmaTech Announces Fourth Quarter and Full Year 2007 Results 3916 6WuXi PharmaTech Announces Fourth Quarter and Full Year 2007 Results 3916 7WuXi PharmaTech Announces Fourth Quarter and Full Year 2007 Results 3916 8WuXi PharmaTech Announces Fourth Quarter and Full Year 2007 Results 3916 9WuXi PharmaTech Announces Fourth Quarter and Full Year 2007 Results 3916 10WuXi PharmaTech Announces Fourth Quarter and Full Year 2007 Results 3916 11WuXi PharmaTech Announces Fourth Quarter and Full Year 2007 Results 3916 12Cardiac Science to Present at the Seventh Annual Invest Northwest Conference 14201 1Cardiac Science to Present at the Seventh Annual Invest Northwest Conference 14201 2deCODE Genetics Announces Full year 2007 Financial Results 3913 1deCODE Genetics Announces Full year 2007 Financial Results 3913 2deCODE Genetics Announces Full year 2007 Financial Results 3913 3deCODE Genetics Announces Full year 2007 Financial Results 3913 4deCODE Genetics Announces Full year 2007 Financial Results 3913 5deCODE Genetics Announces Full year 2007 Financial Results 3913 6deCODE Genetics Announces Full year 2007 Financial Results 3913 7deCODE Genetics Announces Full year 2007 Financial Results 3913 8deCODE Genetics Announces Full year 2007 Financial Results 3913 9
...rCare offers five questions to help women,learn ab...June 12, 2007 – According to a new,GfK Roper...national,nonprofit cancer support organization, wh...id they know at least a fair amount,about breast c...,progress made in treatment. Fewer than one out of...
..., June 13, 2007--Three new drugs for,rheumatoid ar...t,for this difficult and debilitating condition. T... published early Online and in an,upcoming edition...onic,inflammatory joint diseases, affecting 0&midd...sed world. Its typical symptoms are,joint pain, st...
Other Medicine Technology:Women Well-Informed About Breast Cancer, Yet Lacking Knowledge,About Current Treatments, New Survey Finds 2Women Well-Informed About Breast Cancer, Yet Lacking Knowledge,About Current Treatments, New Survey Finds 3Three New Drugs Mark New Era in Rheumatoid Arthritis Treatment 2Three New Drugs Mark New Era in Rheumatoid Arthritis Treatment 3
(Date:8/21/2008)... New names and fresh websit... UME/GME administration software , ... one45 Software, a leading provider of healthcare ... of Cytiva Software Inc. (CRX:TSX.V), announced to...hcare education administration products., , ,Compl...
(Date:8/20/2008)... NEWTON, Mass., Aug. 20 /PRNewswire/ -- Questex M...o-business media company and owner of,American Spa... and the,International Beauty Shows, the Internati...) and the SPATEC appointment events today announce...stry portals SpaTrade (, http://www.SpaTrade.com ...
(Date:8/20/2008)... Survey Report Is Available at http://ww...Newswire/ -- A new survey released today,documents...re leveraging,health information technology (HIT) ...The survey results highlight the need for many HIT...dization and,interoperability to optimize clinical...
(Date:8/20/2008)...use postponed reproductive onset in teen, adult fe...EDNESDAY, Aug. 20 (HealthDay News) -- Alcoholism i...ccording to a study that compared women,s and men,... age when they had their first child. , The re...ian twins born between 1893-1964 (3,634 female and...
Breaking Medicine News(10 mins):Health News:Cytiva's one45 Software Rebrands Healthcare Education Administration Products 2Health News:Cytiva's one45 Software Rebrands Healthcare Education Administration Products 3Health News:Cytiva's one45 Software Rebrands Healthcare Education Administration Products 4Health News:Questex Acquires Leading Spa Industry Portal and Spa Executive Business Networking Site and Events 2Health News:Questex Acquires Leading Spa Industry Portal and Spa Executive Business Networking Site and Events 3Health News:New Health IT Survey for Care Management Services Shows Opportunities for Integration, Standardization and Innovation 2Health News:New Health IT Survey for Care Management Services Shows Opportunities for Integration, Standardization and Innovation 3Health News:Women's Alcohol Use Tied to Delayed Childbearing 2
...n C such as papaya, oranges and blackcurrant may b... that the nutrient could help reduce some of the c... from the University of Warwick have found that th...up' free radicals that are produced in excess in d...
...ect has revealed that one-third of US teenagers wh...lying. It was found during the study that teen...e information on the Internet as compared to direc... also revealed that girls were more likely than bo...
...ws that CANCER death rates for men from the rural ...Despite The fact that cancer survival rates are im...ences between the recovery and death rate of men l...d their urban counterpart. The number of people di...
...buse and Alcoholism (NIAAA), a part of the U.S. Na...five distinct subtypes of alcoholism by analysing...lcohol dependence. Our findings should help dispe...alcoholic, notes first author Dr. Howard B. Moss, ...
Other Medicine News:Health News:One-third of US Teen Netizens are Victims of Cyber-bullying 2Health News:Cancer Deaths of Rural Men on the High 2Health News:Researchers Identify Five Distinct Subtypes of Alcoholism 2Health News:Researchers Identify Five Distinct Subtypes of Alcoholism 3
The DELFIA Platewash is a general purpose microtitration plate and strip washer especially standardized for use with DELFIA diagnostic kits.
SkanWasher 300 with a 25-microplate capacity stacker system. Vacuum pressure and aspiration and dispense probe heights are adjustable. On-board software for user to configure 8 different programs. Ex
...The Labcyte miniGene LW is a new plate washing sys... 96 and 384 channel microplates with flat, V-shape... with 8 or 16 channel nozzle heads. Simple LCD tou...tional plate stacker is available for the miniGene...
...Produce Up to 8000 L/day of Type III Laboratory-gr...ed to produce up to 8000 L/day of Type III laborat...omplete Purification and Control Unit, RiOs system...viding total control of all parameters within the ...
Medicine Products: